Opinion|Videos|July 15, 2024
MARIPOSA Study Insights
Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.
Advertisement
Episodes in this series
- Please comment on the rationale for the use of amivantamab and lazertinib in 1L EGFR-mutant NSCLC and discuss recently presented efficacy and safety data from MARIPOSA. Cho, et al. ESMO 2023. Abstract LBA14
Advertisement
Related to this article
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Advertisement
Advertisement
Trending on OncLive
1
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management
2
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
3
Carotuximab Plus Apalutamide Improves PFS in mCRPC
4
Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in Myeloma
5